Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. PURCHASE AND SALE...Agios Pharmaceuticals, Inc. • February 23rd, 2023 • Pharmaceutical preparations
This PURCHASE AND SALE AGREEMENT (this “Purchase and Sale Agreement”) dated as of October 27, 2022 is by and among Agios Pharmaceuticals, Inc., a Delaware corporation and the Person defined as “Seller” in the Counterparty Agreement (the “Seller”), and the entities set forth in Schedule 1.1 hereto (each individually a “Purchaser”, and collectively, the “Purchasers”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, as representative for the Purchasers (in such capacity, “Purchaser’s Representative”).
CONSULTING AGREEMENTConsulting Agreement • February 23rd, 2023 • Agios Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS CONSULTING AGREEMENT (together with the attached Business Terms Exhibit, the “Agreement”), is entered into as of January 1, 2023 (the “Effective Date”) by and between Agios Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 88 Sidney Street, Cambridge, MA 02139 (“Agios”) and Richa Poddar, an individual with a main address at 32 Anderson Street, #1, Boston, MA 02114 (the “Consultant”). Agios desires to retain Consultant as an independent contractor with respect to certain services as described in this Agreement, and Consultant is willing to provide those services, all as provided in this Agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • February 23rd, 2023 • Agios Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”) is made as of December 5, 2022 by and between Agios Pharmaceuticals, Inc. (the “Company”), and Tsveta Milanova (the “Executive”) (together, the “Parties”).
